Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711014 | 0.76 | CHRM1 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL7708278 | 0.76 | CHRM1 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL7704693 | 0.76 | PDE10A (0.44) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134903 | 0.76 | PDE10A (0.44) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134902 | 0.76 | PDE10A (0.44) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134944 | 0.76 | PDE10A (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL7703924 | 0.76 | PDE10A (0.44) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134975 | 0.75 | CHRM1 (0.36) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134976 | 0.75 | CHRM1 (0.36) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15134977 | 0.75 | CHRM1 (0.36) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | IRAK4 4638/4885PIK3CD 1653/4885PIK3CA 1073/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | IRAK4 4638/4885PIK3CD 1653/4885PIK3CA 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.